Measuring lung stress to identify occult ventilation-induced lung injury in ARDS
测量肺应激以识别 ARDS 患者隐匿性通气引起的肺损伤
基本信息
- 批准号:9918972
- 负责人:
- 金额:$ 12.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-20 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acute respiratory failureAdultAdult Respiratory Distress SyndromeAlveolarAtelectasisAutomobile DrivingBiologicalBiological MarkersBody WeightBreathingChest wall structureClinicalCritical IllnessDataDevelopmentDiseaseDysbarismEdemaEsophagusIL8 geneIndividual DifferencesInflammationInflammatoryInterleukin-6LungLung diseasesManometryMeasuresMechanical StressMechanical ventilationMechanicsMediastinal EmphysemaMorbidity - disease rateNational Heart, Lung, and Blood InstituteParticipantPatient-Focused OutcomesPatientsPhasePhysiologicalPlasmaPleuralPneumothoraxPositive-Pressure RespirationProtocols documentationPulmonary Surfactant-Associated Protein DReportingResearchRiskSafetyStressSubcutaneous EmphysemaTestingTidal VolumeTimeTissuesTitrationsValidationVentilatorVital Statusalveolar epitheliumbasecohortcytokineepithelial injuryesophagus pressureexperiencehigh riskimprovedindividual patientlung injurylung volumemortalitymortality risknovelnovel strategiespersonalized approachpersonalized strategiesprecision medicinepredict clinical outcomepressurepreventprognostic valuepublic health relevancerandomized trialrate of changerespiratorysecondary analysissoluble RAGEstandard of careventilation
项目摘要
PROJECT SUMMARY/ABSTRACT
Acute respiratory distress syndrome (ARDS) occurs in up to one-quarter of all critically ill adults receiving
mechanical ventilation and is associated with high risk of death. In patients with ARDS, the volume of aerated
lung is reduced substantially relative to healthy lung size due to alveolar edema and atelectasis. This smaller
“baby lung,” so-called for its reduced aerated volume available for ventilation, requires smaller tidal volume (Vt)
than would be needed in healthy lungs to prevent regional overdistension. Low Vt ventilation limits ventilation-
induced lung injury (VILI) and improves survival in patients with ARDS. Current standard of care involves
scaling Vt to estimated healthy lung size, i.e. 6 mL/kg predicted body weight (PBW), and limiting end-
inspiratory plateau airway pressure to ≤ 30 cmH2O. Yet, lung stress and strain vary considerably between
ARDS patients receiving the same Vt per PBW due to individual differences in baby lung size and chest wall
mechanics. Ideally, a precision medicine approach to Vt strategy in ARDS would account for these individual
patient differences to better limit maximum lung distension at end-inspiration. By using esophageal manometry
to estimate pleural pressure, one can measure at bedside the mechanical stress across the lung, independent
of chest wall mechanics, as the transpulmonary pressure (lung stress = airway pressure – pleural pressure). In
a prior study, we found peak lung stress measured at end-inspiration was highly correlated with “baby lung”
volume (diseased lung size) but not Vt scaled to PBW (healthy lung size). Peak lung stress also independently
predicted mortality in this cohort. This proposal seeks to (1) advance biological plausibility of peak lung stress
as a bedside marker of ongoing VILI despite low Vt and (2) validate its prognostic utility for predicting patient-
centered outcomes in ARDS. Our central hypothesis is that ARDS patients with higher peak lung stress
experience more VILI and higher mortality despite low Vt ventilation. We will test this hypothesis via a
secondary analysis of clinical, physiological, and biomarker data from the EPVent-2 Trial, a phase-II
multicenter randomized trial of esophageal pressure-guided positive end-expiratory pressure (PEEP) titration in
ARDS. Peak lung stress will be measured daily from respiratory physiological waveforms recorded in all trial
participants. Plasma biomarkers for alveolar epithelial injury (sRAGE, surfactant protein-D) and systemic
inflammation (IL-6, IL-8), as well as overt barotrauma (pneumothorax, pneumomediastinum, subcutaneous
emphysema), will be used as biological and clinical measures of VILI. Vital status and ventilator-free days will
be used to determine prognostic utility of peak lung stress for predicting clinical outcomes in patients with
ARDS. This research will elucidate mechanisms of occult VILI in patients receiving the current standard-of-care
“lung-protective” Vt strategy. Ultimately, results may inform development of novel strategies for individualizing
Vt based on peak lung stress in effort to reduce morbidity and mortality from ARDS.
项目总结/摘要
急性呼吸窘迫综合征(ARDS)发生在所有重症成人中的四分之一,
机械通气并与高死亡风险相关。在ARDS患者中,
由于肺泡水肿和肺不张,肺相对于健康肺的大小显著减小。这个较小
所谓的“婴儿肺”是因为其可用于通气的通气量减少,需要较小的潮气量(Vt)
比健康肺防止局部过度扩张所需的量要多。低Vt通气限制通气-
诱导的肺损伤(VILI),并改善ARDS患者的生存率。目前的护理标准包括
将Vt按比例缩放至估计的健康肺大小,即6 mL/kg预测体重(PBW),并限制终末-
吸气平台气道压≤ 30 cmH 2 O。然而,肺的应力和应变在以下两种情况之间变化很大:
由于婴儿肺大小和胸壁的个体差异,每个PBW接受相同Vt的ARDS患者
力学理想情况下,ARDS中Vt策略的精确医学方法将解释这些个体
患者差异,以更好地限制吸气末的最大肺扩张。通过食管测压
为了估计胸腔压,可以在床边独立测量整个肺部的机械应力
胸壁力学,如经肺压力(肺应力=气道压力-胸膜压力)。在
在先前的研究中,我们发现在吸气末测量的峰值肺应力与“婴儿肺”高度相关。
体积(患病肺大小),但Vt未缩放至PBW(健康肺大小)。峰值肺应力也独立于
预测死亡率。该建议旨在(1)提高峰值肺应力的生物相容性
作为进行性VILI的床旁标志物,尽管Vt较低;(2)验证其预测患者预后的实用性,
以ARDS为中心的结局。我们的中心假设是,具有较高峰值肺应力的ARDS患者
尽管有低Vt通气,VILI和死亡率仍较高。我们将通过一个
对EPVent-2试验(II期)的临床、生理和生物标志物数据进行二次分析
食管压力引导的呼气末正压(PEEP)滴定治疗食管癌的多中心随机试验
ARDS。每天根据所有试验中记录的呼吸生理波形测量峰值肺应力
参与者肺泡上皮损伤的血浆生物标志物(sIgA,表面活性蛋白-D)和全身性
炎症(IL-6,IL-8),以及明显的气压伤(气胸,肺气肿,皮下
肺气肿)将用作VILI的生物学和临床测量。生命状态和无呼吸机天数将
用于确定峰值肺应力预测患者临床结局的预后效用,
ARDS。这项研究将阐明接受当前标准治疗的患者中隐匿性VILI的机制
“肺保护”VT策略。最终,研究结果可能会为个性化的新策略的发展提供信息。
以肺压力峰值为基础的Vt,旨在降低ARDS的发病率和死亡率。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Emerging concepts in ventilation-induced lung injury.
- DOI:10.12688/f1000research.20576.1
- 发表时间:2020-01-01
- 期刊:
- 影响因子:0
- 作者:Madahar, Purnema;Beitler, Jeremy R
- 通讯作者:Beitler, Jeremy R
Incorporating baseline functional status to improve validity of neurological outcome assessments following cardiac arrest.
纳入基线功能状态以提高心脏骤停后神经系统结果评估的有效性。
- DOI:10.1016/j.resuscitation.2019.07.006
- 发表时间:2019
- 期刊:
- 影响因子:6.5
- 作者:Eng,KevinJ;Yang,JennyZ;Tyagi,Sanjeev;Odish,MazenF;Rosen,Sheri;Sell,RebeccaE;Beitler,JeremyR
- 通讯作者:Beitler,JeremyR
Strategies to Adjust Positive End-Expiratory Pressure in Patients With ARDS-Reply.
调整 ARDS-Reply 患者呼气末正压的策略。
- DOI:10.1001/jama.2019.7888
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Beitler,JeremyR;Talmor,Daniel
- 通讯作者:Talmor,Daniel
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy R. Beitler其他文献
Inhaled sedation versus propofol in respiratory failure in the ICU (INSPiRE-ICU2): study protocol for a multicenter randomized controlled trial
- DOI:
10.1186/s13063-025-08791-0 - 发表时间:
2025-03-31 - 期刊:
- 影响因子:2.000
- 作者:
Brian O’Gara;Alexis L. Serra;Joshua A. Englert;Alisha Sachdev;Robert L. Owens;Steven Y. Chang;Pauline K. Park;Daniel Talmor;Ida Sverud;Peter Sackey;Jeremy R. Beitler - 通讯作者:
Jeremy R. Beitler
Monitoring esophageal pressure
- DOI:
10.1007/s00134-024-07401-y - 发表时间:
2024-04-11 - 期刊:
- 影响因子:21.200
- 作者:
Lise Piquilloud;Jeremy R. Beitler;François M. Beloncle - 通讯作者:
François M. Beloncle
Volatile anesthetics for ICU sedation: the future of critical care or niche therapy?
- DOI:
10.1007/s00134-022-06842-7 - 发表时间:
2022-09-03 - 期刊:
- 影响因子:21.200
- 作者:
Jeremy R. Beitler;Daniel Talmor - 通讯作者:
Daniel Talmor
Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions
- DOI:
10.1007/s00134-020-05942-6 - 发表时间:
2020-02-03 - 期刊:
- 影响因子:21.200
- 作者:
Elena Spinelli;Tommaso Mauri;Jeremy R. Beitler;Antonio Pesenti;Daniel Brodie - 通讯作者:
Daniel Brodie
Lung-protective sedation: moving toward a new paradigm of precision sedation
- DOI:
10.1007/s00134-022-06901-z - 发表时间:
2022-10-14 - 期刊:
- 影响因子:21.200
- 作者:
Elias Baedorf Kassis;Jeremy R. Beitler;Daniel Talmor - 通讯作者:
Daniel Talmor
Jeremy R. Beitler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy R. Beitler', 18)}}的其他基金
1/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)
1/2:精确通气以减轻通气引起的肺损伤(预防 VILI)
- 批准号:
10738958 - 财政年份:2023
- 资助金额:
$ 12.15万 - 项目类别:
相似海外基金
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6564818 - 财政年份:2001
- 资助金额:
$ 12.15万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6410976 - 财政年份:2000
- 资助金额:
$ 12.15万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370267 - 财政年份:2000
- 资助金额:
$ 12.15万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6418789 - 财政年份:2000
- 资助金额:
$ 12.15万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370266 - 财政年份:2000
- 资助金额:
$ 12.15万 - 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
- 批准号:
6370265 - 财政年份:2000
- 资助金额:
$ 12.15万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6302122 - 财政年份:1999
- 资助金额:
$ 12.15万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6309780 - 财政年份:1999
- 资助金额:
$ 12.15万 - 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
- 批准号:
6109540 - 财政年份:1998
- 资助金额:
$ 12.15万 - 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
- 批准号:
6265845 - 财政年份:1998
- 资助金额:
$ 12.15万 - 项目类别:














{{item.name}}会员




